Gapping up
In reaction to earnings/guidance:
- HIMS +25.3%, ROVR +16.3%, TWOU +13.5%, RIDE +11.4%, SEDG +10.8%, LPSN +9%, PRIM +8.7%, EVBG +8%, PLNT +7.9%, TASK +6.6%, EHTH +6.6%, SANM +5.6%, NWN +5%, TGI +4.9%, NFE +4.3%, RYTM +4.3%, PTVE +4%, IGT +4%, GFS +4%, QGEN +3.7%, TDC +3.6%, ME +3.4%, DD +3.3%, NXST +3.3%, COTY +3.2%, ACCO +3.1%, BLDR +3%, CERT +2.9%, CG +2.9%, XNCR +2.7%, SEAT +2.7%, ACRS +2.7%, HAIN +2.6%, OSH +1.8%, TAC +1.8%, AMWL +1.4%, DO +1.4%, NCLH +1.4%, HLGN +1.3%, FN +1.2%, ARVN +1%
Other news:
- ARWR +2.7% (presents new phase 2 data on cardiometabolic pipeline)
- AMGN +2% (presents new analysis from Phase 3 FOURIER and FOURIER studies of Repatha)
- ARRY +2% (to supply solar trackers for one of its largest solar projects in the US)
- CNX +1.9% (partners with New Frontier to leverage abated methane emissions)
- PGTI +1.1% (detected a ransomware infection that impacted some of its network)
- ENVA +1% (authorizes new $150 mln share repurchase program)
Analyst comments:
- PLAY +3.3% (upgraded to Buy from Hold at Deutsche Bank)
- SMG +3% (upgraded to Overweight from Equal Weight at Barclays)
- ASML +2.2% (initiated with an Overweight at Morgan Stanley)
- GLP +2.1% (upgraded to Buy from Hold at Stifel)
- SQ +1.6% (upgraded to Outperform from Neutral at Macquarie)